Forgot Password?
Return to Course Listing

CME: Endometrial cancer: treatment updates and gaps in management

Activity Description / Statement of Need:

In this online, self-learning activity:

Endometrial cancer, a type of cancer that originates in the lining of the uterus, is the most common gynecologic cancer and the fourth most common cancer in women living in the United States, with over 66,000 cancers of the uterine corpus diagnosed every year and 13,000 associated deaths. The vast majority of women are diagnosed with endometrial cancer after the age of 50, and risk factors are obesity, level of physical activity, increasing age, and the presence of a variety of comorbid, chronic health conditions. Levels of estrogen and progesterone fluctuate during the menstrual cycle, resulting in cell proliferation and differentiation that may lead to abnormalities that contribute to malignancies later in life. The costs associated with endometrial cancer may amount to tens of thousands of dollars per patient, depending on the stage of disease upon diagnosis.

This activity has been designed to bring HCP's knowledge of identification, management, and patient care strategies for endometrial cancer up to date and to improve their competence and performance in treating the disease.

Target Audience:

The following HCPs: Medical oncologists and pathologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other clinicians who commonly encounter patients with endometrial cancer.


Commercial Support Disclosure: This program is supported by an educational grant from Merck.

This activity is free of charge.


Release Date: July 09, 2021 -- Expiration Date: July 09, 2022

Faculty: Dario Roque, MD

Agenda

Faculty introduction, disclosures

Introduction content: review of endometrial cancer

  • Epidemiology and statistics
  • Causes and risk factors for endometrial cancer
  • Pathogenesis, clinical features, and prevention
  • Clinical presentation and diagnosis by stage and etiology; related challenges [Learning objective #1]
  • Biomarkers’ roles in disease prognosis [Learning objective #2]

Treatment of endometrial cancer with a focus on advanced and recurrent disease

  • Brief review of loco-regional disease treatment approaches
  • Treatment approaches for advanced disease: [Learning objective #s 3 & 4]

·       Chemotherapy-naïve patients

·       Disease recurrence

·       Mismatch repair-deficient

·       Microsatellite-instable

·       High tumor mutational burden

  • Biomarkers and their roles in treatment [Learning objective #2]
  • Investigational therapy [Learning objective #3]
  • Treatment challenges

·       Adverse effect identification and management [Learning objective #s 3 & 4]

·       Gaps in care and modifiable healthy equity challenges [Learning objective #5]

  • Patient case(s) [Learning objective #4]

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Recall the challenges in the diagnosis of endometrial cancer and their impact on outcomes.
  • Describe the role of biomarker/molecular testing in determining the prognosis and treatment of endometrial cancer.
  • List evidence-based treatment considerations and emerging therapies in the clinical management of endometrial cancer.
  • Formulate a treatment plan for a patient with endometrial cancer.
  • Discuss challenges and modifiable health equity factors associated with treating subpopulations of patients with endometrial cancer.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME-MOC_badge

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPath MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Pathology's (ABPath) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath MOC credit.

PhysiciansFor maintenance of certification (MOC) credit, you must enter your board certification ID # and birth date correctly. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC credit for this activity. Please note: Not all activities on this site provide MOC credit. If this activity does not specify that it provides MOC credit in this section, then it does NOT provide MOC credit.

Pharmacists

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-21-027-H01-P.  ACPE Accreditation effective 7/09/2021, expires 7/09/2022. This is an Application (A)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.  ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Dario R. Roque, MD,  Assistant Professor, Division of Gynecologic Oncology, Northwestern University Feinberg School of Medicine, has received financial compensation for the following: Speaker’s Bureau from GSK and Merck; Advisory Panel from Myriad; and Surgical Proctor from Intuitive Surgical.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merck.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Recurrent and metastatic endometrial cancer: Therapeutic updates and optimizing treatment

Biosimilars in the treatment of malignancies and supportive care

Metastatic Colon Cancer: Updates from the 2020 ASCO (American Society of Clinical Oncology) Annual Meeting

Updates in chronic lymphocytic leukemia (CLL) treatment paradigms